Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 1/2017

01-01-2017 | Review

Surgical cure for type 2 diabetes by foregut or hindgut operations: a myth or reality? A systematic review

Authors: Yan Mei Goh, Zaher Toumi, Ravindra S. Date

Published in: Surgical Endoscopy | Issue 1/2017

Login to get access

Abstract

Background

Bariatric surgery results in remission of type 2 diabetes mellitus in a significant proportion of patients. Animal research has proposed the foregut and hindgut hypotheses as possible mechanisms of remission of T2DM independent of weight loss. These hypotheses have formed the basis of investigational procedures designed to treat T2DM in non-obese (in addition to obese) patients. The aim of this study was to review the procedures that utilise the foregut and hindgut hypotheses to treat T2DM in humans.

Methods

A systematic review was conducted to identify the investigational procedures performed in humans that are based on the foregut and hindgut hypotheses and then to assess their outcomes.

Results

Twenty-four studies reported novel procedures to treat T2DM in humans; only ten utilised glycated haemoglobin A1c (HbA1c) in their definition of remission. Reported remission rates were 20–40 % for duodenal–jejunal bypass (DJB), 73–93 % for duodenal–jejunal bypass with sleeve gastrectomy (DJB-SG), 62.5–100 % for duodenal–jejunal bypass sleeve (DJBS) and 47–95.7 % for ileal interposition with sleeve gastrectomy (II-SG). When using a predetermined level of HbA1c to define remission, the remission rates were lower (27, 63, 0 and 65 %) for DJB, DJB-SG, DJBS and II-SG.

Conclusions

The outcomes of the foregut- and hindgut-based procedures are not better than the outcomes of just one of their components, namely sleeve gastrectomy. The complexity of these procedures in addition to their comparable outcomes to a simpler operation questions their utility.
Literature
1.
Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222(3):339–350; discussion 50–52
2.
Thaler JP, Cummings DE (2009) Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 150(6):2518–2525PubMedCrossRef
3.
4.
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(3):248–256 e5
5.
Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ et al (2013) Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309(21):2240–2249PubMedPubMedCentralCrossRef
6.
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366(17):1577–1585PubMedCrossRef
7.
Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S et al (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299(3):316–323PubMedCrossRef
8.
Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE et al (2012) Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366(17):1567–1576PubMedPubMedCentralCrossRef
9.
Patriti A, Aisa MC, Annetti C, Sidoni A, Galli F, Ferri I et al (2007) How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. Surgery 142(1):74–85PubMedCrossRef
10.
Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A et al (2004) Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest. 113(4):635–645PubMedPubMedCentralCrossRef
11.
Hansen EN, Tamboli RA, Isbell JM, Saliba J, Dunn JP, Marks-Shulman PA et al (2011) Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol 300(5):G795–G802PubMedPubMedCentralCrossRef
12.
Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G et al (2006) The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244(5):741–749PubMedPubMedCentralCrossRef
13.
Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Laferrere B (2009) Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg 19(2):217–229PubMedCrossRef
14.
Laferrere B (2011) Diabetes remission after bariatric surgery: is it just the incretins? Int J Obes (Lond) 35(Suppl 3):S22–S25CrossRef
15.
World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series, vol 894, pp i–vii, 1–253
16.
Lakdawala M, Bhasker A (2008) Report: Asian consensus meeting on metabolic surgery. recommendations for the use of bariatric and gastrointestinal metabolic surgery for treatment of obesity and type II diabetes mellitus in the Asian population: August 9th and 10th, 2008, Trivandrum, India. Obes Surg 20(7):929–936CrossRef
17.
18.
Cohen R, Caravatto PP, Correa JL, Noujaim P, Petry TZ, Salles JE et al (2012) Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis 8(4):375–380PubMedCrossRef
19.
Huang C-K, Goel R, Tai C-M, Yen Y-C, Gohil VD, Chen X-Y (2013) Novel metabolic surgery for type II diabetes mellitus: loop duodenojejunal bypass with sleeve gastrectomy. Surg Laparosc Endosc Percutaneous Tech 23(6):481–485CrossRef
20.
Klein S, Fabbrini E, Patterson BW, Polonsky KS, Schiavon CA, Correa JL et al (2012) Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity (Silver Spring) 20(6):1266–1272CrossRef
21.
Geloneze B, Geloneze SR, Chaim E, Hirsch FF, Felici AC, Lambert G et al (2012) Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg 256(1):72–78PubMedCrossRef
22.
Lee HC, Kim MK, Kwon HS, Kim E, Song KH (2010) Early changes in incretin secretion after laparoscopic duodenal-jejunal bypass surgery in type 2 diabetic patients. Obes Surg 20(11):1530–1535PubMedCrossRef
23.
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M (2008) First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 4(1):55–59PubMedCrossRef
24.
Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM et al (2010) A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 251(2):236–243PubMedCrossRef
25.
Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG et al (2009) Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 11(11):725–732PubMedCrossRef
26.
DePaula AL, Stival AR, DePaula CC, Halpern A, Vencio S (2012) Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases. J Gastrointest Surg 16(5):967–976PubMedCrossRef
27.
DePaula AL, Macedo AL, Mota BR, Schraibman V (2009) Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc 23(6):1313–1320PubMedCrossRef
28.
DePaula AL, Stival AR, Halpern A, Vencio S (2011) Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients. Obes Surg 21(5):668–675PubMedCrossRef
29.
Kota SK, Ugale S, Gupta N, Naik V, Kumar KV, Modi KD (2012) Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. Indian J Endocrinol Metab 16(4):589–598PubMedPubMedCentralCrossRef
30.
Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P et al (2009) Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther 11(12):785–789PubMedCrossRef
31.
Tinoco A, El-Kadre L, Aquiar L, Tinoco R, Savassi-Rocha P (2011) Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World J Surg 35(10):2238–2244PubMedCrossRef
32.
Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F (2007) Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 3(2):195–197PubMedCrossRef
33.
Ferzli GS, Dominique E, Ciaglia M, Bluth MH, Gonzalez A, Fingerhut A (2009) Clinical improvement after duodenojejunal bypass for nonobese type 2 diabetes despite minimal improvement in glycemic homeostasis. World J Surg 33(5):972–979PubMedCrossRef
34.
Ramos AC, Galvao Neto MP, de Souza YM, Galvao M, Murakami AH, Silva AC et al (2009) Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI <30 kg/m2 (LBMI). Obes Surg 19(3):307–312PubMedCrossRef
35.
de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvao Neto MP et al (2012) Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther 14(2):183–189PubMedCrossRef
36.
de Moura EG, Orso IR, da Martins BC, Lopes GS, de Oliveira SL, dos Galvao-Neto MP et al (2011) Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg 21(7):941–947PubMedCrossRef
37.
Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D et al (2012) Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg 255(6):1080–1085PubMedCrossRef
38.
Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L et al (2011) Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 25(9):3028–3033PubMedCrossRef
39.
Raj PP, Kumaravel R, Chandramaliteeswaran C, Vaithiswaran V, Palanivelu C (2012) Laparoscopic duodenojejunal bypass with sleeve gastrectomy: preliminary results of a prospective series from India. Surg Endosc 26(3):688–692PubMedCrossRef
40.
Cohen RV, Neto MG, Correa JL, Sakai P, Martins B, Schiavon CA et al (2013) A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab 98(2):E279–E282PubMedCrossRef
41.
de Jonge C, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND et al (2013) Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 11(11):1517–1520PubMedCrossRef
42.
Rubino F, Marescaux J (2004) Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239(1):1PubMedPubMedCentralCrossRef
43.
Wang TT, Gao HD, Zhang GY, Liu CZ, Feng JB, Frezza EE (2008) Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg 247(6):968–975PubMedCrossRef
44.
Pacheco D, de Luis DA, Romero A, Sagrado MG, Conde R, Izaola O et al (2007) The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 194(2):221–224PubMedCrossRef
45.
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346(21):1623–1630PubMedCrossRef
46.
Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, Papavramidis ST (2006) Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatmen—a prospective study. Obes Surg 16(11):1425–1432PubMedCrossRef
47.
Van Citters GW, Lin HC (1999) The ileal brake: a fifteen-year progress report. Curr Gastroenterol Rep 1(5):404–409PubMedCrossRef
48.
Lin HC, Zhao X-T, Chu AW, Lin YP, Wang L (1997) Fiber-supplemented enteral formula slows intestinal transit by intensifying inhibitory feedback from the distal gut. Am J Clin Nutr 65(6):1840–1844PubMed
49.
Brown NJ, Worlding J, Rumsey R, Read N (1988) The effect of guar gum on the distribution of a radiolabelled meal in the gastrointestinal tract of the rat. Br J Nutr 59(02):223–231PubMedCrossRef
50.
Zhang G, Hasek LY, Lee B-H, Hamaker BR (2015) Gut feedback mechanisms and food intake: a physiological approach to slow carbohydrate bioavailability. Food Funct 6(4):1072–1089PubMedCrossRef
51.
Raybould HE (1998) Does your gut taste? Sensory transduction in the gastrointestinal tract. Physiology 13(6):275–280
52.
Baskota A, Li S, Dhakal N, Liu G, Tian H (2015) Bariatric surgery for type 2 diabetes mellitus in patients with BMI <30 kg/m2: a systematic review and meta-analysis. PLoS ONE 10(7):e0132335PubMedPubMedCentralCrossRef
53.
Lee WJ, Almulaifi AM, Tsou JJ, Ser KH, Lee YC, Chen SC (2015) Duodenal-jejunal bypass with sleeve gastrectomy versus the sleeve gastrectomy procedure alone: the role of duodenal exclusion. Surg Obes Relat Dis 11(4):765–770PubMedCrossRef
54.
Rao WS, Shan CX, Zhang W, Jiang DZ, Qiu M (2015) A meta-analysis of short-term outcomes of patients with type 2 diabetes mellitus and BMI </= 35 kg/m2 undergoing Roux-en-Y gastric bypass. World J Surg 39(1):223–230PubMedCrossRef
55.
Abbatini F, Capoccia D, Casella G, Coccia F, Leonetti F, Basso N (2012) Type 2 diabetes in obese patients with body mass index of 30–35 kg/m2: sleeve gastrectomy versus medical treatment. Surg Obes Relat Dis 8(1):20–24PubMedCrossRef
56.
Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC (2008) Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI >35 and <35 kg/m2. J Gastrointest Surg 12(5):945–952PubMedCrossRef
57.
Gill RS, Birch DW, Shi X, Sharma AM, Karmali S (2010) Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis 6(6):707–713PubMedCrossRef
58.
Gagner M (2011) Laparoscopic sleeve gastrectomy with ileal interposition (SGIT): a modified duodenal switch for resolution of type 2 diabetes mellitus in lesser obese patients (BMI <35). World J Surg 35(1):109–110PubMedCrossRef
59.
Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J (2000) Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 232(4):515–529PubMedPubMedCentralCrossRef
60.
Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G et al (2003) Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238(4):467–484; discussion 84–85
61.
Wittgrove AC, Clark GW (2000) Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results, with 3-60 month follow-up. Obes Surg 10(3):233–239PubMedCrossRef
62.
Gill RS, Birch DW, Shi X, Sharma AM, Karmali S (2010) Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis 6(6):707–713PubMedCrossRef
63.
Abbatini F, Rizzello M, Casella G, Alessandri G, Capoccia D, Leonetti F et al (2010) Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc 24(5):1005–1010PubMedCrossRef
64.
Nocca D, Guillaume F, Noel P, Picot MC, Aggarwal R, El Kamel M et al (2011) Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg 21(6):738–743PubMedCrossRef
Metadata
Title
Surgical cure for type 2 diabetes by foregut or hindgut operations: a myth or reality? A systematic review
Authors
Yan Mei Goh
Zaher Toumi
Ravindra S. Date
Publication date
01-01-2017
Publisher
Springer US
Published in
Surgical Endoscopy / Issue 1/2017
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-016-4952-4

Other articles of this Issue 1/2017

Surgical Endoscopy 1/2017 Go to the issue

OriginalPaper

Is current surgery resident and GI fellow training adequate to pass FES?

Review

A systematic review of low-cost laparoscopic simulators

OriginalPaper

C-reactive protein can be an early predictor of postoperative complications after gastrectomy for gastric cancer

OriginalPaper

National disparities in minimally invasive surgery for pancreatic tumors

Dynamic Manuscript

Application of clip traction in endoscopic submucosal dissection to the treatment of early esophageal carcinoma and precancerous lesions

OriginalPaper

Value of routine polysomnography in bariatric surgery